Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DRRX Stock Forecast 2025-2026
$0.73
Current Price
$22.66M
Market Cap
Buy 2
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to DRRX Price Targets
+1,064.4%
To High Target of $8.50
+824.7%
To Median Target of $6.75
+584.9%
To Low Target of $5.00
DRRX Price Momentum
+23.7%
1 Week Change
-2.7%
1 Month Change
-31.1%
1 Year Change
-2.7%
Year-to-Date Change
-61.2%
From 52W High of $1.88
+40.4%
From 52W Low of $0.52
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Durect (DRRX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on DRRX and similar high-potential opportunities.
Latest DRRX Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, DRRX has a bullish consensus with a median price target of $6.75 (ranging from $5.00 to $8.50). Currently trading at $0.73, the median forecast implies a 824.7% upside. This outlook is supported by 2 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Francois Brisebois at Oppenheimer, suggesting a 584.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DRRX Analyst Ratings
2
Buy
1
Hold
0
Sell
DRRX Price Target Range
Low
$5.00
Average
$6.75
High
$8.50
Current: $0.73
Latest DRRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DRRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 27, 2025 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $0.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $0.00 |
| Sep 26, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $0.00 |
| May 22, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $0.00 |
| May 15, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $0.00 |
| Apr 1, 2024 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $5.00 |
| Mar 28, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $0.00 |
| Nov 9, 2023 | JonesTrading | Sean Kim | Hold | Downgrade | $0.00 |
| Nov 8, 2023 | HC Wainwright & Co. | Ed Arce | Neutral | Downgrade | $0.00 |
| Nov 7, 2023 | HC Wainwright & Co. | Neutral | Downgrade | $0.00 | |
| Aug 10, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $27.00 |
| Aug 10, 2023 | Cantor Fitzgerald | Kristen Kluska | Overweight | Maintains | $41.00 |
| May 17, 2023 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $44.00 |
| May 9, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $32.00 |
| Apr 11, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $32.00 |
| Mar 14, 2023 | JonesTrading | Sean Kim | Buy | Initiates | $37.00 |
| Mar 8, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $32.00 |
| Dec 7, 2022 | Oppenheimer | Francois Brisebois | Outperform | Maintains | $32.00 |
| May 5, 2021 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| Feb 3, 2021 | Chardan Capital | Michael Morabito | Buy | Maintains | $8.00 |
Durect Corporation (DRRX) Competitors
The following stocks are similar to Durect based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Durect Corporation (DRRX) Financial Data
Durect Corporation has a market capitalization of $22.66M with a P/E ratio of -2.7x. The company generates $2.03M in trailing twelve-month revenue with a 96.2% profit margin.
Revenue growth is -83.0% quarter-over-quarter, while maintaining an operating margin of -753.9% and return on equity of -154.0%.
Valuation Metrics
Market Cap
$22.66M
Enterprise Value
$13.06M
P/E Ratio
-2.7x
PEG Ratio
-0.7x
Price/Sales
11.2x
Growth & Margins
Revenue Growth (YoY)
-83.0%
Gross Margin
+72.3%
Operating Margin
-753.9%
Net Margin
+96.2%
EPS Growth
-245.9%
Financial Health
Cash/Price Ratio
+52.1%
Current Ratio
1.7x
Debt/Equity
24.2x
ROE
-154.0%
ROA
-37.2%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Durect Corporation (DRRX) Business Model
About Durect Corporation
What They Do
Biopharmaceutical company developing innovative drugs.
Business Model
Durect Corporation generates revenue by developing and commercializing pharmaceutical products, focusing on pain management and chronic conditions. The company leverages its unique extended-release drug delivery technologies and collaborates with other pharmaceutical companies to enhance drug development and distribution.
Additional Information
Founded in 1998 and based in Cupertino, California, Durect is dedicated to addressing significant medical needs and improving patient quality of life while reducing long-term healthcare costs. Its investigational products, particularly in post-surgical pain management, highlight its commitment to enhancing recovery outcomes.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
21
CEO
Dr. James E. Brown D.V.M.
Country
United States
IPO Year
2000
Website
www.durect.comDurect Corporation (DRRX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Catalyst Pharmaceutical (CPRX) Q1 Earnings and Revenues Top Estimates
Catalyst (CPRX) delivered earnings and revenue surprises of 28.30% and 8.92%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 07, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
DURECT Corporation (NASDAQ:DRRX) will hold its Q4 2024 earnings call on March 26, 2025, at 4:30 PM ET, featuring key executives and financial analysts.
Why It Matters
DURECT's earnings call provides insights into financial performance and future strategies, impacting stock valuation and investor sentiment. Key executives' updates could signal growth or risks ahead.
Source: Seeking Alpha
Market Sentiment:
Neutral
DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
1 month ago
Quick Summary
Larsucosterol Phase 2b trial results for alcohol-associated hepatitis published in NEJM Evidence, with additional data presented in November 2024; Phase 3 trial design is informed. Earnings call on March 26.
Why It Matters
Positive Phase 2b trial results for Larsucosterol could indicate strong potential in treating alcohol-associated hepatitis, impacting stock prices and investor sentiment in biotech.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Durect (DRRX) reported a quarterly loss of $0.06 per share, matching the Zacks Consensus Estimate, an improvement from a loss of $0.27 per share a year prior.
Why It Matters
Durect's smaller quarterly loss signals improving financial health, potentially boosting investor confidence and stock performance compared to last year's results.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
DURECT Corporation (Nasdaq: DRRX) will report its Q4 and full year 2024 financial results on March 26, 2025, focusing on epigenetic therapies for serious conditions.
Why It Matters
DURECT Corporation's upcoming financial results could reveal insights into its performance and progress in developing transformative therapies, impacting stock valuation and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
3 months ago
Quick Summary
DURECT Corporation (Nasdaq: DRRX) announced a leadership change with James E. appointed on February 4, 2025. Further details on the announcement were not provided.
Why It Matters
Leadership changes can impact a company's strategy and performance, influencing stock prices and investor confidence. Monitor DURECT's direction under new leadership.
Source: PRNewsWire
Market Sentiment:
Neutral
DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence
3 months ago
Quick Summary
DURECT Corporation (Nasdaq: DRRX) announced the publication of AHFIRM trial data in NEJM Evidence, which informs the design of its upcoming Phase 3 trial.
Why It Matters
New trial data and peer-reviewed publication enhance credibility for DURECT Corporation, potentially impacting stock price and investor confidence ahead of the Phase 3 trial.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About DRRX Stock
What is Durect Corporation's (DRRX) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Durect Corporation (DRRX) has a median price target of $6.75. The highest price target is $8.50 and the lowest is $5.00.
Is DRRX stock a good investment in 2025?
According to current analyst ratings, DRRX has 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.73. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DRRX stock?
Wall Street analysts predict DRRX stock could reach $6.75 in the next 12 months. This represents a 824.7% increase from the current price of $0.73. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Durect Corporation's business model?
Durect Corporation generates revenue by developing and commercializing pharmaceutical products, focusing on pain management and chronic conditions. The company leverages its unique extended-release drug delivery technologies and collaborates with other pharmaceutical companies to enhance drug development and distribution.
What is the highest forecasted price for DRRX Durect Corporation?
The highest price target for DRRX is $8.50 from at , which represents a 1,064.4% increase from the current price of $0.73.
What is the lowest forecasted price for DRRX Durect Corporation?
The lowest price target for DRRX is $5.00 from Francois Brisebois at Oppenheimer, which represents a 584.9% increase from the current price of $0.73.
What is the overall DRRX consensus from analysts for Durect Corporation?
The overall analyst consensus for DRRX is bullish. Out of 6 Wall Street analysts, 2 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $6.75.
How accurate are DRRX stock price projections?
Stock price projections, including those for Durect Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2025 9:31 PM UTC